- Halozyme Therapeutics (HALO -3.9%) slips after being downgraded to EqualWeight at Barclays.
- The firm cites concern over FDA approval for certain product lines, saying it believes that PH20 remains a commercially viable platform, but FDA concerns over antibodies to PH20 put a damper on the approvability of any blood product such as HyQ and Cinryze in combination with PH20.
- Barclays thinks the overhang will likely limit the stock's upside potential - especially in light of the VPHM announcement.
Halozyme cut to EqualWeight at Barclays
Aug 2 2013, 13:35 ET